Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF<sup>V600</sup>-mutant advanced melanoma patients: a propensity-matched survival analysis.

More about this publication

British journal of cancer
  • Volume 124
  • Issue nr. 10
  • Pages 1746
  • Publication date 01-05-2021

This site uses cookies

This website uses cookies to ensure you get the best experience on our website.